Answers are grounded in this paper and cite their sources.
Background Claudin 18.2 (CLDN18.2) is an established therapeutic biomarker in advanced gastric cancer, but its expression in early gastric cancer remains incompletely characterized. This study aimed to describe the prevalence, clinicopathological associations, and regional staining patterns of CLDN18.2 in early gastric cancer. Methods We retrospectively analyzed 54 early gastric cancers resected by endoscopic submucosal dissection. CLDN18.2 immunohistochemistry was evaluated using computer-assisted semiquantitative image analysis with pathologist review. Positivity was defined as moderate-to-strong (≥2+) membranous staining in ≥75% of viable tumor cells. Regional status was assessed in three tumor-center regions (Regions A-C) and one deepest/advancing tumor area (Region D). Results CLDN18.2 positivity was identified in 38 of 54 tumors (70%) and was not significantly associated with histological differentiation (two-sided Fisher–Freeman–Halton exact P = .229), Ki-67 expression, p53 staining pattern, or MLH1 status. Thirty-five tumors (65%) showed consistent status across the four regions, whereas 19 (35%) showed regional discordance. A tumor-center-positive/Region D-negative pattern was observed in 8 of 54 tumors (15%). Positivity differed across the four paired regions (Cochran Q = 26.90, P < .001), and Region D had a lower positivity rate than each tumor-center region in pairwise analyses (all Bonferroni-adjusted P ≤ .006). Conclusions CLDN18.2 expression was relatively common in this early gastric cancer cohort, and regional staining variability was observed in a subset of tumors. These findings extend the pathological characterization of CLDN18.2 in early gastric cancer by describing its prevalence and regional expression patterns.
No takes yet. Share an insight, caveat, or question.
He et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: